Loading
ZFP36L1 (mRNA decay activator protein ZFP36L1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Zinc-finger RNA-binding protein that destabilises several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis. Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signalling events to the mRNA decay machinery. Functions by recruiting the CCR4-NOT deadenylase complex and components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.90, affected pathway 0.31, genetic association 0.55, somatic mutation 0.48). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Bladder Urothelial Carcinoma, Malignant Lymphoma.
In plain words · ZFP36L1 (mRNA decay activator protein ZFP36L1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
ZFP36L1 (mRNA decay activator protein ZFP36L1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.
Zinc-finger RNA-binding protein that destabilises several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis.
No product in this corpus aims at ZFP36L1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA ZFP36L1: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 2,922 nTPM); no normal tissue stained high; highest cancer staining cervical cancer (2 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Bladder & urothelial cancer, Lymphoma); Open Targets associates it with 1 specific cancer type at or above 0.5 (breast carcinoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q07352; CIViC gene ZFP36L1; IntOGen ZFP36L1; Human Protein Atlas ZFP36L1 tissue; Open Targets ENSG00000185650 associations
First described 1993. Earliest sequence paper UniProt cites for the protein: Barnard R.C. et al, Nucleic Acids Res, 1993, "Coding sequence of ERF-1, the human homologue of Tis11b/cMG1, members of the Tis11 family of early response genes". Source.
Sources: HGNC HGNC:1107 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q07352 (protein name, function text, keywords and locations (REST API)); CIViC gene ZFP36L1 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000185650 (association with cancer (MONDO_0004992) 0.52; (GraphQL API, CC0)); IntOGen ZFP36L1 (driver in 2 cohorts (Act 1, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Zinc-finger RNA-binding protein that destabilises several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis. Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signalling events to the mRNA decay machinery. Functions by recruiting the CCR4-NOT deadenylase complex and components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes. Also induces the degradation of ARE-containing mRNAs even in absence of poly(A) tail. Binds to 3'-UTR ARE of numerous mRNAs. Positively regulates early adipogenesis by promoting ARE-mediated mRNA decay of immediate early genes (IEGs). Location: Nucleus; Cytoplasm; Cytoplasmic granule; Cytoplasm, P-body (UniProt). Locus 14q24.1 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: lineage enriched (granulocytes 2,922 nTPM).
No normal tissue stained high.
Medium only: carcinoid, endometrial cancer, head and neck cancer, ovarian cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ZFP36L1" OR ABSTRACT:"ZFP36L1" OR TITLE:"ZFP36 like 1 zinc finger CCCH-type" OR ABSTRACT:"ZFP36 like 1 zinc finger CCCH-type" OR TITLE:"mRNA decay activator protein ZFP36L1" OR ABSTRACT:"mRNA decay activator protein ZFP36L1" OR TITLE:"Berg36" OR ABSTRACT:"Berg36" OR TITLE:"ERF1" OR ABSTRACT:"ERF1" OR TITLE:"TIS11B" OR ABSTRACT:"TIS11B") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZFP36L1, not a curated reading list.